Clinical Trial to Assess the Safety and Efficacy of Investigational Product in Patients Due to Hypospadias Treatment Failure

Overview

The purpose of this trial is to assess the safety and efficacy of Holour in patients suffering from hypospadias treatment failure. Holour is intended for urethral replacement and is made from ex vivo expanded autologous oral mucosal cells including stem cells.

Full Title of Study: “Prospective, Open-label, Uncontrolled Pilot Clinical Trial to Assess the Safety and Efficacy of Autologous Cultured Oral Mucosa Grafts for Urethral Reconstruction in Patients Due to Hypospadias Treatment Failure”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2024

Detailed Description

Holour is a prospective, open-label, uncontrolled pilot clinical trial phase i/ii. The aim of this clinical trial is to perform a tissue engineering therapy to assess the safety (at 3 and 12 months) and efficacy (at 12 months) of the autologous treatment. Patients will be screened according to the study inclusion and exclusion criteria and will be candidate for the treatment if all eligibility criteria are met. Up to 8 patients will be treated by means of autologous cultured oral mucosa grafts containing oral mucosa stem cells. Holour is produced by ex vivo expansion of cells obtained from oral mucosa biopsy collected from patient. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where the epithelial cells will be isolated, expanded and prepared as final graft to be implanted. Holour administration will be planned according to the procedures and the need of the patient. The entire procedure envisages the following steps: 1. Oral mucosa biopsy to manufacture autologous grafts of Holour. 2. Penile urethroplasty in two stages: – First stage: application of holour on the wound bed prepared according to standard surgery. – Second stage: penis reconstruction according to standard surgical procedure. The surgical procedures may be followed by a post-implantation treatment (if necessary) with corticosteroids and antibiotics. The treatment includes a single administration of Holour; in case of "failure" of the first procedure eligible patients can undergo to a second implantation. Three months after the transplantation, primary endpoint will be evaluated by the investigator. The study completion will be reached when 1 year (secondary endpoint) of follow-up after the last transplant in the last patient will be accomplished. The end of the trial is defined as the last visit of the last patient after the last treatment if any.

Interventions

  • Drug: “Ex vivo” expanded autologous human oral epithelium containing stem cells
    • The treatment includes a single administration of investigational product through a dedicated surgical procedure of penis wound bed preparation, epithelial surface adaption and product application followed by urethra tubularization and penis reconstruction.

Arms, Groups and Cohorts

  • Experimental: Urethral reduced functionality and/or lesions due to previous hypospadias treatment failure
    • The first step consists in a small oral mucosa biopsy collection by surgeon under general anaesthesia. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where the epithelial cells will be isolated, expanded and prepared as final graft to be implanted. The treatment for urethra reconstruction required a two stage urethroplasty: First stage: application of Holour on the wound bed prepared according to standard surgery The penis will be immobilized for some days after this operation. Second stage: surgical procedure for urethral tubularization and penile reconstruction according to standard surgical procedure. The surgical procedures may be followed by a post-implantation treatment (if necessary) with corticosteroids and antibiotics.

Clinical Trial Outcome Measures

Primary Measures

  • Number and percentage of patients experiencing AESI
    • Time Frame: 3 months after treatment
    • To demonstrate the safety of Holour in terms of AESI (persistent fever, infections)
  • Number and percentage of patients experiencing ADRs
    • Time Frame: 3 months after treatment
    • To demonstrate the safety of Holour in terms of ADRs
  • Number and percentage of patients experiencing SAEs
    • Time Frame: 3 months after treatment
    • To demonstrate the safety of Holour in terms of SAEs
  • Number and percentage of patients experiencing Serious ADRs
    • Time Frame: 3 months after treatment
    • To demonstrate the safety of Holour in terms of Serious ADRs
  • Number and percentage of patients experiencing AESI
    • Time Frame: 12 months after treatment
    • To demonstrate the safety of Holour in terms of AESI (persistent fever, infections)
  • Number and percentage of patients experiencing ADRs
    • Time Frame: 12 months after treatment
    • To demonstrate the safety of Holour in terms of AESI ADRs
  • Number and percentage of patients experiencing SAEs
    • Time Frame: 12 months after treatment
    • To demonstrate the safety of Holour in terms of SAEs
  • Number and percentage of patients experiencing Serious ADRs
    • Time Frame: 12 months after treatment
    • To demonstrate the safety of Holour in terms of Serious ADRs
  • Number of patients with implantation success
    • Time Frame: 12 months after treatment
    • Implantation success is defined on the basis of the degree of clinical (no lesions, no significant retractions) epithelial stability on the transplanted area. The degree of epithelial stability will be evaluated by visual inspection, cistouretrography, uretroscophy and checked for evaluating reepithelialization, erosions, infection, etc. and documented with photos with measures.
  • percentage of patients with implantation success
    • Time Frame: 12 months after treatment
    • Implantation success is defined on the basis of the degree of clinical (no lesions, no significant retractions) epithelial stability on the transplanted area. The degree of epithelial stability will be evaluated by visual inspection, cistouretrography, uretroscophy and checked for evaluating reepithelialization, erosions, infection, etc. and documented with photos with measures.

Secondary Measures

  • Number of patients with the treatment efficacy after Holour implantation and surgical reconstruction
    • Time Frame: up to 1 year after implantation
    • Regeneration of a clinically normal appearing urethra epithelium with absence of detectable erosions/retractions and Clinical functionality (uroflowmetry) after the second step (urethral reconstruction) of transplant.
  • Evaluation of the percentage of re-epithelialization
    • Time Frame: up to 1 year after implantation
    • Evaluation of the percentage of re-epithelialization
  • Evaluation of the clinical epithelial stability on the transplanted area by visual inspections
    • Time Frame: up to 1 year after implantation
    • Evaluation of the regeneration of a clinically normal appearing epithelium with absence of detectable erosions/retractions
  • Evaluation of scar retraction presence
    • Time Frame: up to 1 year after implantation
    • Evaluation of the penile retraction due to presence/absence of scars
  • Evaluation of uroflowmetry rate
    • Time Frame: From 3 to 12 months after the treatment
    • Evaluation of the change of uroflowmetry compared to the baseline value with change of the curve shape and significant increase of the qmax flow rate;
  • Evaluation of the post-void residual volume through uroflowmetry
    • Time Frame: From 3 to 12 months after the treatment
    • Evaluation of the change of the post-void residual compared to the baseline
  • Evaluation of the presence and severity of surgical complications
    • Time Frame: up to 1 year after implantation
    • Presence and severity of surgical complications using the Clavien Dindo scale with the classification into 5 grades (I, II, III, IV and V from no need for clinical intervention to the death of the patient)
  • Evaluation of the adeverse events in terms of SAEs, AESI, ADR Serious ADRs,
    • Time Frame: up to 1 year after implantation
    • Evaluation of the adeverse events in terms of SAEs, AESI, ADR Serious ADRs,

Participating in This Clinical Trial

Inclusion Criteria

1. Signed and dated informed consent prior to any study-related procedures (Caregivers); Patients whose parents/legal representatives have been thoroughly informed of the aim of the study procedures and provided signed and dated written informed consent; 2. Male patients between 5 and 17 years old (less than 18 years old); 3. Need for urethroplasty in failed hypospadias treatment; 4. Hypospadias complications shown by clinical evaluation, uroflowmetry with post-micturition residual evaluation and/or retrograde urethrography and/or urethroscopy; 5. Uroflowmetry rate: Uroflowmetry with a plateau-shaped curve and low qmax according to paediatric uroflow normograms; 6. Absence of other contraindications to HOLOUR implantation based on investigator's judgement; 7. A cooperative attitude to follow up the study procedures (Caregivers in case of minors). Exclusion Criteria:

1. Known or suspected intolerances against anaesthesia; 2. Bad general condition (ECOG index >2); 3. Clinical and/or laboratory signs of acute systemic infections and/or severe inflammation at the time of screening. Patient can be re-screened after appropriate treatment; 4. Severe systemic disease (i.e. uncompensated diabetes); 5. Stenosis or retraction secondary to medical conditions other than hypospadias failure (i.e. radiotherapy, lichen sclerosis, etc…); 6. Allergy, sensitivity or intolerance to drugs or excipients (hypersensitivity to any of the excipients listed in Investigator's brochure or in this protocol):

  • Transport medium (Dulbecco's Modified Eagles Medium supplemented with L-glutamine) – Fibrin support; 7. Contraindications to the post- treatment local or systemic antibiotics and/or corticosteroids; 8. UTI or urine culture positive requiring a re-screening of patient; 9. Contraindications to undergo extensive surgical procedures; 10. Clinically significant or unstable concurrent disease or other clinical contraindications to stem cell implantation based on investigator's judegment or other concomitant medical conditions affecting grafting procedure; 11. Patients and parents/tutor unlikely to comply with the study protocol or unable to understand the nature and scope of the study or the possible benefits or unwanted effects of the study procedures and treatments; 12. Participation in another clinical trial where conventional investigational drug was received less than 1 months prior to screening visit; 13. Patients who received surgical procedure within 6 months prior to screening visit; 14. Anaesthesia or severe hypoesthesia of the area; 15. Diagnosis of local or systemic neoplastic disease.

Gender Eligibility: Male

Minimum Age: 5 Years

Maximum Age: 17 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Holostem Terapie Avanzate s.r.l.
  • Collaborator
    • Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Graziella Pellegrini, Professor, Study Director, Holostem Terapie Avanzate s.r.l.
    • Gianantonio Manzoni, MD, Principal Investigator, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.